NO308215B1 - Oligonukleotidanaloger, deres anvendelse og farmasøytiske sammensetning inneholdende disse - Google Patents

Oligonukleotidanaloger, deres anvendelse og farmasøytiske sammensetning inneholdende disse

Info

Publication number
NO308215B1
NO308215B1 NO930199A NO930199A NO308215B1 NO 308215 B1 NO308215 B1 NO 308215B1 NO 930199 A NO930199 A NO 930199A NO 930199 A NO930199 A NO 930199A NO 308215 B1 NO308215 B1 NO 308215B1
Authority
NO
Norway
Prior art keywords
aryl
alkyl
seh
alkoxy
equal
Prior art date
Application number
NO930199A
Other languages
English (en)
Norwegian (no)
Other versions
NO930199D0 (no
NO930199L (no
Inventor
Eugen Uhlmann
Anuschirwan Peyman
Gerard O'malley
Matthias Helsberg
Irvin Winkler
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of NO930199D0 publication Critical patent/NO930199D0/no
Publication of NO930199L publication Critical patent/NO930199L/no
Publication of NO308215B1 publication Critical patent/NO308215B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
NO930199A 1992-01-22 1993-01-21 Oligonukleotidanaloger, deres anvendelse og farmasøytiske sammensetning inneholdende disse NO308215B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4201662 1992-01-22

Publications (3)

Publication Number Publication Date
NO930199D0 NO930199D0 (no) 1993-01-21
NO930199L NO930199L (no) 1993-07-23
NO308215B1 true NO308215B1 (no) 2000-08-14

Family

ID=6450030

Family Applications (1)

Application Number Title Priority Date Filing Date
NO930199A NO308215B1 (no) 1992-01-22 1993-01-21 Oligonukleotidanaloger, deres anvendelse og farmasøytiske sammensetning inneholdende disse

Country Status (17)

Country Link
EP (1) EP0552766B1 (fr)
JP (1) JP3717081B2 (fr)
KR (1) KR930016437A (fr)
AT (1) ATE217880T1 (fr)
AU (1) AU661365B2 (fr)
CA (1) CA2087818C (fr)
DE (1) DE59310285D1 (fr)
DK (1) DK0552766T3 (fr)
ES (1) ES2177532T3 (fr)
FI (1) FI115214B (fr)
HU (1) HU227794B1 (fr)
IL (1) IL104461A (fr)
NO (1) NO308215B1 (fr)
NZ (1) NZ245720A (fr)
PL (1) PL172257B1 (fr)
PT (1) PT552766E (fr)
ZA (1) ZA93422B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378825A (en) * 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5646261A (en) * 1992-01-22 1997-07-08 Hoechst Aktiengesellschaft 3'-derivatized oligonucleotide analogs with non-nucleotidic groupings, their preparation and use
DK0593901T3 (da) 1992-09-24 1997-10-27 Hoechst Ag Oligoribonucleotid- og ribozym-analoge med terminale 3-3- og 5-5-bindinger.
EP0602524A1 (fr) * 1992-12-15 1994-06-22 Hoechst Aktiengesellschaft Sondes marqués par chemiluminescence et leur utilisation dans épreuves des sondes
CA2153505A1 (fr) * 1993-01-08 1994-07-21 Jin-Yan Tang Synthese de blocs dimeres et leur utilisation dans la formation d'oligonucleotides
US6087491A (en) * 1993-01-08 2000-07-11 Hybridon, Inc. Extremely high purity oligonucleotides and methods of synthesizing them using dimer blocks
JPH08508714A (ja) * 1993-01-25 1996-09-17 ハイブライドン インコーポレイテッド オリゴヌクレオチド・アルキルホスホネートおよびアルキルホスホノチオエート
CA2114355A1 (fr) * 1993-01-29 1994-07-30 Hidehiko Furukawa Oligodesoxyribonucleotides modifies, leur preparation et leur utilisation therapeutique
US5532130A (en) * 1993-07-20 1996-07-02 Dyad Pharmaceutical Corporation Methods and compositions for sequence-specific hybridization of RNA by 2'-5' oligonucleotides
DE4331670A1 (de) * 1993-09-17 1995-03-23 Hoechst Ag Neue Antisense-Oligonucleotide gegen HSV-1 sowie deren Herstellung
DE4338704A1 (de) 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
US6919441B2 (en) 1994-03-14 2005-07-19 Aventis Pharma Deutschland Gmbh Polyamide-oligonucleotide derivatives, their preparation and use
DE4408528A1 (de) * 1994-03-14 1995-09-28 Hoechst Ag Peptid-Oligonucleotid-Derivate, deren Herstellung und Verwendung
US5726297A (en) * 1994-03-18 1998-03-10 Lynx Therapeutics, Inc. Oligodeoxyribonucleotide N3' P5' phosphoramidates
JP3482209B2 (ja) * 1994-03-18 2003-12-22 ジェロン・コーポレーション オリゴヌクレオチドｎ３’→ｐ５’ホスホルアミデート：合成および化合物；ハイブリダイゼーションおよびヌクレアーゼ耐性特性
US5599922A (en) * 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
DE4415370A1 (de) * 1994-05-02 1995-11-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
US5986076A (en) * 1994-05-11 1999-11-16 Trustees Of Boston University Photocleavable agents and conjugates for the detection and isolation of biomolecules
US5696248A (en) * 1994-06-15 1997-12-09 Hoechst Aktiengesellschaft 3'-modified oligonucleotide derivatives
US6150510A (en) 1995-11-06 2000-11-21 Aventis Pharma Deutschland Gmbh Modified oligonucleotides, their preparation and their use
DE4438918A1 (de) * 1994-11-04 1996-05-09 Hoechst Ag Modifizierte Oligonukleotide, deren Herstellung sowie deren Verwendung
DE19502912A1 (de) 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilisierte Oligonucleotide
ATE206131T1 (de) * 1995-03-13 2001-10-15 Aventis Pharma Gmbh Phosphonomonoesternnukleinsäuren, verfahren zu ihrer herstellung und ihre verwendung
US6326487B1 (en) 1995-06-05 2001-12-04 Aventis Pharma Deutschland Gmbh 3 modified oligonucleotide derivatives
US5859233A (en) * 1996-02-21 1999-01-12 Lynx Therapeutics, Inc. Synthons for synthesis of oligonucleotide N3-P5 phosphoramidates
US5684143A (en) * 1996-02-21 1997-11-04 Lynx Therapeutics, Inc. Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates
GB9606158D0 (en) * 1996-03-23 1996-05-29 Ciba Geigy Ag Chemical compounds
PT808898E (pt) * 1996-05-24 2004-10-29 Aventis Pharma Gmbh Reagente e metodo para inibicao da expressao de n-ras
DE19627898A1 (de) * 1996-07-11 1998-01-15 Hoechst Ag Festphasensynthese von Oligonucleotiden
BR9809242A (pt) * 1997-05-05 2000-06-27 Hoechst Marion Russel Deutschl Nucleotìdeos anti-sentido modificados complementares a uma seção do gene ha-ras humano
WO1999019474A1 (fr) * 1997-10-14 1999-04-22 Sankyo Company, Limited Oligodesoxyribonucleotides modifies comportant la sequence tggg
EP1004661A1 (fr) 1998-11-11 2000-05-31 DALLI-WERKE WÄSCHE- und KÖRPERPFLEGE GmbH & Co. KG Granulé de haute densité, procédé pour sa production, son utilisation en tant que désintégrant pour tablettes
DE19935303A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonukleotide zur Inhibierung der Expression von humanem eg5
DE19935302A1 (de) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Konjugate und Verfahren zu deren Herstellung sowie deren Verwendung zum Transport von Molekülen über biologische Membranen
DE10133915A1 (de) 2001-07-12 2003-02-06 Aventis Pharma Gmbh Neue Oligoribonucleotid-Derivate zur gezielten Hemmung der Genexpression
KR20110007263A (ko) 2003-08-28 2011-01-21 노파르티스 아게 블런트-말단 및 3＇-변형체를 갖는 간섭 ｒｎａ 이중나선
GB0608838D0 (en) 2006-05-04 2006-06-14 Novartis Ag Organic compounds
EP3643782A1 (fr) 2008-02-11 2020-04-29 Phio Pharmaceuticals Corp. Polynucléotides d'arni modifiés et leurs utilisations
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
US8664189B2 (en) 2008-09-22 2014-03-04 Rxi Pharmaceuticals Corporation RNA interference in skin indications
US9074211B2 (en) 2008-11-19 2015-07-07 Rxi Pharmaceuticals Corporation Inhibition of MAP4K4 through RNAI
WO2010090762A1 (fr) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Duplexes d'arn avec régions de nucléotide phosphorothioate à brin unique pour fonctionnalité supplémentaire
CN105131067B (zh) 2010-03-24 2019-02-19 雷克西制药公司 皮肤与纤维化症候中的rna干扰
WO2011119852A1 (fr) 2010-03-24 2011-09-29 Rxi Pharmaceuticals Corporation Composés d'arni de taille réduite s'auto-administrant
WO2011119871A1 (fr) 2010-03-24 2011-09-29 Rxi Phrmaceuticals Corporation Arn interférant dans des indications oculaires
JP6772062B2 (ja) 2013-12-02 2020-10-21 フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． 癌の免疫療法
WO2015125845A1 (fr) * 2014-02-20 2015-08-27 塩野義製薬株式会社 Modification de site phosphate d'acide nucléique contenant un hétérocycle non aromatique contenant de l'azote
EP3137119B1 (fr) 2014-04-28 2020-07-01 Phio Pharmaceuticals Corp. Procédés de traitement du cancer au moyen d'un acide nucléique ciblant mdm2
CN107073294A (zh) 2014-09-05 2017-08-18 阿克赛医药公司 使用靶向tyr或mmp1的核酸治疗老化和皮肤病症的方法
WO2017007825A1 (fr) 2015-07-06 2017-01-12 Rxi Pharmaceuticals Corporation Procédés pour le traitement de troubles neurologiques à l'aide d'une petite molécule synergique et approche thérapeutique utilisant des acides nucléiques
CN108135923B (zh) 2015-07-06 2021-03-02 菲奥医药公司 靶向超氧化物歧化酶1（sod1）的核酸分子
CN109563509B (zh) 2015-10-19 2022-08-09 菲奥医药公司 靶向长非编码rna的减小尺寸的自递送核酸化合物
JP7353301B2 (ja) 2018-05-07 2023-09-29 アルニラム ファーマスーティカルズ インコーポレイテッド 肝臓外送達

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3239888A1 (de) * 1982-10-28 1984-05-03 Hubert Prof. Dr. 2000 Hamburg Köster Verfahren zur herstellung von oligonucleosidphosphonaten
US4739044A (en) * 1985-06-13 1988-04-19 Amgen Method for derivitization of polynucleotides
DE3751468T2 (de) * 1986-10-30 1996-02-29 Daicel Chem Verfahren zur herstellung von oligonukleotiden und verbindungen zur bildung hochmolekularer schutzgruppen.
US4816571A (en) * 1987-06-04 1989-03-28 Applied Biosystems, Inc. Chemical capping by phosphitylation during oligonucleotide synthesis
DE69034150T2 (de) * 1989-10-24 2005-08-25 Isis Pharmaceuticals, Inc., Carlsbad 2'-Modifizierte Oligonukleotide
US5210015A (en) * 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
GB9021625D0 (en) * 1990-10-04 1990-11-21 Ici Plc Synthesis of oligonucleotides

Also Published As

Publication number Publication date
NZ245720A (en) 1995-12-21
ES2177532T3 (es) 2002-12-16
AU3191093A (en) 1993-07-29
CA2087818C (fr) 2007-07-10
HU9300162D0 (en) 1993-04-28
PT552766E (pt) 2002-10-31
IL104461A0 (en) 1993-05-13
DE59310285D1 (de) 2002-06-27
FI115214B (fi) 2005-03-31
EP0552766A2 (fr) 1993-07-28
JPH05310779A (ja) 1993-11-22
FI930220A0 (fi) 1993-01-20
DK0552766T3 (da) 2002-08-19
PL172257B1 (pl) 1997-08-29
EP0552766B1 (fr) 2002-05-22
FI930220A (fi) 1993-07-23
KR930016437A (ko) 1993-08-26
NO930199D0 (no) 1993-01-21
HU227794B1 (en) 2012-03-28
ATE217880T1 (de) 2002-06-15
ZA93422B (en) 1993-09-16
PL297515A1 (en) 1993-09-06
IL104461A (en) 2001-05-20
JP3717081B2 (ja) 2005-11-16
HUT63173A (en) 1993-07-28
AU661365B2 (en) 1995-07-20
EP0552766A3 (en) 1994-09-07
CA2087818A1 (fr) 1993-07-23
NO930199L (no) 1993-07-23

Similar Documents

Publication Publication Date Title
NO308215B1 (no) Oligonukleotidanaloger, deres anvendelse og farmasøytiske sammensetning inneholdende disse
CA2320390C (fr) Conjugues d'anp et d'adn et procedes de preparation desdits conjugues
DE69815342D1 (de) Sulfonatfreie cyaninfarbstoffe zur markierung von nukleosiden und nukleotiden
FI20051072A (fi) Polyamidi-oligonukleotidijohdoksia, niiden valmistus ja niiden käyttö
EP0233053A2 (fr) Procédé pour la détection d'oligonucléotides séparés par électrophorèse
DE69415343T2 (de) 2'-amido-und 2'-peptido-modifizierte oligonukleotide
ATE172468T1 (de) Synthetische katalytische oligonukleotide
DE59712871D1 (de) Heterocyclische verbindungen und deren verwendung in der detektion von nucleinsäuren
DE60002989D1 (de) Verfahren zur herstellung von morpholinonukleotiden und verwendung derselben zur analyse und markierung von nukleinsäuresequenzen
DK1296997T3 (da) Baseanaloger
DE69501705D1 (de) Verfahren zur Herstellung von optisch aktiven Piperazinderivaten und Zwischenprodukten für ihre Herstellung
FR2787109B1 (fr) Nouveaux derives de 1,2-dithiolane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Legal Events

Date Code Title Description
MK1K Patent expired